RecruitingNCT06633016
ABX-002 or placebo added to antidepressants for depression
About this title
Read the official source — NCT06633016Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Birmingham and 49 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 20, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 230
- Sponsor
- Autobahn Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06633016
- Official title
Show the full official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Birmingham · Chandler · Phoenix
44 more locations
- Tucson
- Anaheim
- Encino
- Glendale
- Long Beach
- Los Alamitos
- Newport Beach
- Oceanside
- Orange
- Rancho Cucamonga
- San Jose
- Walnut Creek
- West Covina
- Cromwell
- Brandon
- Hialeah
- Jacksonville
- Lake City
- Miami
- Miami Gardens
- Orlando
- Tampa
- Atlanta
- Decatur
- Peachtree Corners
- Savannah
- Elgin
- Boston
- Watertown
- Saint Charles
- Las Vegas
- Berlin
- Brooklyn
- New York
- Staten Island
- Beachwood
- Oklahoma City
- North Charleston
- Beaumont
- San Antonio
- Sherman
- Orem
- Fairfax
- Bellevue
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Autobahn Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including ABX-002.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
